Mesenchymal Stromal Cell Infusion Viable Option for Treatment of GVHD

Share this content:
Infusion of mesenchymal stromal cells could be a treatment option for steroid-refractory acute graft-versus-host disease.
Infusion of mesenchymal stromal cells could be a treatment option for steroid-refractory acute graft-versus-host disease.

Infusion of mesenchymal stromal cells (MSC) could be a treatment option for patients with steroid-refractory acute graft-versus-host disease (GVHD), according to results of a study published online ahead of print.1

GVHD, for which no approved treatments are available, is a major limitation in hematopoietic stem-cell transplantation. While some physicians use an infusion of MSC, its efficacy is still a matter of debate. 

A group of researchers performed a meta-analysis and systematic review to evaluate the benefit of MSC treatment in patients with steroid-resistant GVHD.

The researchers identified a total of 13 non-randomized studies (N=336) at moderate risk of bias and 6 studies contained data for the primary outcome analysis (N=119). Primary outcome was defined as survival at 6 months from first infusion of MSCs.

RELATED: More Aggressive Tumor Biology in African Americans With Breast Cancer

Results showed that survival at 6 months was 63% (95% CI, 50 – 74; I2=41%). Survival was not linked to age, MSC culture medium, or dose of MSCs.

The authors concluded that randomized trials are critical in order to assess different treatments for steroid-refractory GVHD.

Reference

  1. Hashmi S, Ahmed M, Murad H, et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus host disease: systematic review and meta-analysis [published online ahead of print November 26, 2015]. Lancet Haematol. doi: 10.1016/S2352-3026(15)00224-0.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs